DMAC EBITDA Growth
Diamedica Therapeutics Inc · EBITDA Growth
DMAC EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-26.91%period ending
DMAC TTM EBITDA YoY % (-160.50% → -26.91%)
Year-over-year change
High-resolution chart · PNG
DMAC ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -26.9065% | |
| -30.0791% | |
| -34.1333% | |
| -47.3042% | |
| -48.8878% | |
| -40.3576% | |
| -26.243% | |
| -21.7954% | |
| -21.2909% | |
| -25.9999% | |
| -43.4046% | |
| -35.356% | |
| -20.9845% | |
| -13.4143% | |
| 0.5907% | |
| 9.9904% | |
| 6.3496% | |
| 2.7313% | |
| -8.5865% | |
| -18.7291% | |
| -26.7774% | |
| -22.6824% | |
| -2.1958% | |
| -24.0902% | |
| -26.6867% | |
| -35.2284% | |
| -115.7338% | |
| -106.379% | |
| -122.9022% | |
| -156.7459% | |
| -43.016% | |
| -38.4982% | |
| -9.7929% | |
| -4.0734% | |
| -85.2241% | |
| -56.5132% | |
| -147.9886% | |
| -137.7256% | |
| -48.9133% | |
| -27.7227% | |
| 38.7528% | |
| 60.6875% | |
| 70.8017% | |
| 67.5369% | |
| 57.8891% | |
| 45.7332% | |
| 21.5269% | |
| 28.9551% | |
| 29.8044% | |
| 27.7516% | |
| 17.787% | |
| -16.2826% | |
| -41.477% | |
| -79.9468% | |
| -69.8542% | |
| -87.4702% | |
| -129.644% | |
| -112.1728% | |
| -180.7838% | |
| -85.1766% | |
| -21.1566% | |
| -16.9991% | |
| 25.0892% | |
| -0.0073% | |
| -5.6941% | |
| 10.7915% | |
| -9.3463% | |
| 20.4576% | |
| 3.8338% | |
| 12.4359% | |
| 10.4364% | |
| -32.8651% | |
| -29.7668% | |
| -335.4909% | |
| -459.9836% | |
| -627.9191% | |
| -1,481.358% | |
| -266.7707% | |
| -160.5008% |